May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
A Hyperspectral Retinal Imaging System: A Spectral–Spatial Comparison Of Clinically Significant Macular Edema (CSME)
Author Affiliations & Notes
  • G. Zamora
    Biomedical Imaging, Kestrel Corporation, Albuquerque, NM
  • P.W. Truitt
    Biomedical Imaging, Kestrel Corporation, Albuquerque, NM
  • S.C. Nemeth
    Biomedical Imaging, Kestrel Corporation, Albuquerque, NM
  • S.R. Russell
    Department of Ophthalmology, Unversity of Iowa, Iowa City, IA
  • A. Durukan
    Department of Ophthalmology, Unversity of Iowa, Iowa City, IA
  • P. Soliz
    Biomedical Imaging, Kestrel Corporation, Albuquerque, NM
  • Footnotes
    Commercial Relationships  G. Zamora, Kestrel Corporation E; P.W. Truitt, Kestrel Corporation E, P; S.C. Nemeth, Kestrel Corporation E; S.R. Russell, University of Iowa F; A. Durukan, University of Iowa F; P. Soliz, Kestrel Corporation I, E, P.
  • Footnotes
    Support  NMTB DAMD 17–97–2–7016
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 457. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      G. Zamora, P.W. Truitt, S.C. Nemeth, S.R. Russell, A. Durukan, P. Soliz; A Hyperspectral Retinal Imaging System: A Spectral–Spatial Comparison Of Clinically Significant Macular Edema (CSME) . Invest. Ophthalmol. Vis. Sci. 2004;45(13):457.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To demonstrate the effectiveness of a hyperspectral retinal imaging system for differentiating edematous macula from unaffected macula in a patient with clinically significant macular edema (CSME) by spectral signatures. Methods: A 33–year old male with a 15 year course of Type I diabetes mellitus and CSME confirmed by fluorescein angiography, and an age–matched control subject were dilated in one eye using 1% mydriacyl and 2.5% phenylephrine. Data were collected across the non–edematous regions, and if present, the edematous regions of the macula to produce 64 spectral bands simultaneously across the visible and near infrared region of the spectrum with a spectral resolution of 4nm. The same area was spatially imaged using a digital high resolution scene camera. Spectral signatures of clinically identifiable edema and unaffected macular tissue were analyzed using Principal Component Analysis (PCA) to identify features for classification. Results: Three different macula conditions or spectral phenotypes were identified from the data of the CSME subject. These were judged to represent the normal macular tissue, macula–CSME transitionzone, and definite CSME. PCA identified that only the first three principal components were required to categorize the tissue phenotypes. In addition to the identification of normal regions in CSME–associated retina, the normal fundus had a reduced variation in feature values suggesting an overlap between features. Conclusions: We have demonstrated the utility of a technique to characterize CSME in diabetic retinopathy based on hyperspectral data. Spectral feature variability may be related to reduced variability in the normal tissue composition compared to that of pathologic tissue. Further studies using this technology may demonstrate its utility to detect tissue changes pre–clinically. Disclaimer: This work was sponsored by the National Medical Technology Testbed, Inc. (NMTB) and the department of the Army, Cooperative Agreement Number (DAMD 17–97–2–7016). The content of the information in this work does not necessarily reflect the position or the policy of the government or NMTB. No official endorsement should be inferred.

Keywords: imaging/image analysis: clinical • imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) • diabetic retinopathy 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×